Needham Reiterates Buy on Pliant Therapeutics, Maintains $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a price target of $45.
August 10, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pliant Therapeutics' stock rating has been reiterated as 'Buy' by Needham analyst Joseph Stringer, with a maintained price target of $45.
The reiteration of a 'Buy' rating by a reputable analyst like Joseph Stringer is a positive signal for investors. The maintained price target of $45 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100